Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

Real-World Comparison of PCSK9 Treatments and Deaths and Medical Utilization

Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis.

European heart journal. Cardiovascular pharmacotherapy

Citation & Authors

Eur Heart J Cardiovasc Pharmacother. 2024;10(6):505-514.

Chi-Hsien Huang; Shiow-Ing Wang; Frank S Fan; Hsueh-Ju Lu; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

This retrospective TriNetX study evaluated PCSK9-related lipid-lowering treatment using statin users as comparators. After matching, all-cause mortality was lower (aHR 0.717; 95% CI 0.673–0.763), as were hospitalization, emergency visits, intensive care, and mechanical ventilation. This was an observational comparison; treatment-selection differences and residual confounding may still influence the findings, which require confirmation in randomized trials.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗